CA3043396A1 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases - Google Patents

Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases Download PDF

Info

Publication number
CA3043396A1
CA3043396A1 CA3043396A CA3043396A CA3043396A1 CA 3043396 A1 CA3043396 A1 CA 3043396A1 CA 3043396 A CA3043396 A CA 3043396A CA 3043396 A CA3043396 A CA 3043396A CA 3043396 A1 CA3043396 A1 CA 3043396A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3043396A
Other languages
English (en)
French (fr)
Inventor
Chantal Therese Tasset
Pille HARRISON
Rene Alexandre Galien
John Sargent Sundy
John G. Mchutchison
Thomas O'RIORDAN
Neelufar Mozaffarian
Uptal Dinesh Patel
Timothy R. Watkins
David L. Gossage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CA3043396A1 publication Critical patent/CA3043396A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3043396A 2016-11-10 2017-11-09 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases Abandoned CA3043396A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB201618959 2016-11-10
GB201618962 2016-11-10
GB201618963 2016-11-10
GB1618959.9 2016-11-10
GB1618962.3 2016-11-10
GB1618963.1 2016-11-10
GB1618961.5 2016-11-10
GB1618960.7 2016-11-10
GB1618964.9 2016-11-10
GB201618961 2016-11-10
GB201618964 2016-11-10
GB201618960 2016-11-10
PCT/EP2017/078701 WO2018087202A1 (en) 2016-11-10 2017-11-09 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
CA3043396A1 true CA3043396A1 (en) 2018-05-17

Family

ID=60388032

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043396A Abandoned CA3043396A1 (en) 2016-11-10 2017-11-09 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases

Country Status (8)

Country Link
US (1) US20190314382A1 (cg-RX-API-DMAC7.html)
EP (1) EP3538103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019534304A (cg-RX-API-DMAC7.html)
AU (1) AU2017358703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043396A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019117562A (cg-RX-API-DMAC7.html)
TW (1) TW201821080A (cg-RX-API-DMAC7.html)
WO (1) WO2018087202A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019132654A1 (en) * 2017-12-27 2019-07-04 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020009566A1 (en) * 2018-07-04 2020-01-09 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN115282168B (zh) * 2022-08-30 2024-05-31 马应龙大健康有限公司 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用
CN119157881A (zh) * 2024-09-25 2024-12-20 Jje有限公司 Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111956A1 (en) 2003-07-03 2007-05-17 Japan Science And Technology Agency Remedy for sarcoidosis and method of treating the same
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
DK2830662T3 (da) * 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
KR20170134750A (ko) 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
AU2016259023A1 (en) * 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth

Also Published As

Publication number Publication date
EP3538103A1 (en) 2019-09-18
TW201821080A (zh) 2018-06-16
JP2019534304A (ja) 2019-11-28
WO2018087202A1 (en) 2018-05-17
AU2017358703A1 (en) 2019-05-09
US20190314382A1 (en) 2019-10-17
RU2019117562A (ru) 2020-12-10
RU2019117562A3 (cg-RX-API-DMAC7.html) 2021-02-09

Similar Documents

Publication Publication Date Title
EP3538103A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US12370195B2 (en) Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
Malemud et al. Targeting JAK/STAT signaling pathway in inflammatory diseases
US11512092B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20220251101A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US20210290651A1 (en) Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
JP7751362B2 (ja) 乾癬性関節炎の治療方法
CN105473142A (zh) 用二氢吡嗪并-吡嗪治疗癌症
JP2023542878A (ja) 多発性硬化症を治療するためのlou064
US11993606B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2022204721A1 (en) Alk-5 inhibitors and uses thereof
US20220117966A1 (en) Method of treating fibrosis
US12570664B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2025248468A1 (en) Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
Barkham et al. 262 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies
WO2009110416A1 (ja) 併用剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230509